IL143010A0 - Peptidic vectors for transporting substances through the hemato-encephalic barrier - Google Patents
Peptidic vectors for transporting substances through the hemato-encephalic barrierInfo
- Publication number
- IL143010A0 IL143010A0 IL14301099A IL14301099A IL143010A0 IL 143010 A0 IL143010 A0 IL 143010A0 IL 14301099 A IL14301099 A IL 14301099A IL 14301099 A IL14301099 A IL 14301099A IL 143010 A0 IL143010 A0 IL 143010A0
- Authority
- IL
- Israel
- Prior art keywords
- hemato
- transporting substances
- encephalic barrier
- peptidic vectors
- peptidic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Image Analysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9815074A FR2786397B1 (fr) | 1998-11-30 | 1998-11-30 | Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc |
| PCT/FR1999/002938 WO2000032236A1 (fr) | 1998-11-30 | 1999-11-26 | Vecteurs peptidiques de substances a travers la barriere hemato-encephalique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL143010A0 true IL143010A0 (en) | 2002-04-21 |
Family
ID=9533370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14301099A IL143010A0 (en) | 1998-11-30 | 1999-11-26 | Peptidic vectors for transporting substances through the hemato-encephalic barrier |
| IL143010A IL143010A (en) | 1998-11-30 | 2001-05-07 | Peptidic vectors for transporting substances through the hemato-encephalic barrier |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL143010A IL143010A (en) | 1998-11-30 | 2001-05-07 | Peptidic vectors for transporting substances through the hemato-encephalic barrier |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7399747B1 (xx) |
| EP (1) | EP1135168B1 (xx) |
| JP (1) | JP2002531420A (xx) |
| AT (1) | ATE293460T1 (xx) |
| AU (1) | AU777811B2 (xx) |
| CA (1) | CA2352491A1 (xx) |
| DE (1) | DE69924870T2 (xx) |
| ES (1) | ES2242453T3 (xx) |
| FR (1) | FR2786397B1 (xx) |
| IL (2) | IL143010A0 (xx) |
| PT (1) | PT1135168E (xx) |
| WO (1) | WO2000032236A1 (xx) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19933492B4 (de) | 1999-07-16 | 2008-01-10 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung |
| GB0103110D0 (en) | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
| FR2821272B1 (fr) * | 2001-02-23 | 2004-12-17 | Synt Em | Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant |
| FR2829940A1 (fr) * | 2001-09-27 | 2003-03-28 | Synt Em | Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central |
| FR2830016B1 (fr) * | 2001-09-27 | 2004-06-25 | Synt Em | Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau |
| FR2840810B1 (fr) * | 2002-06-18 | 2005-02-11 | Synt Em | Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires |
| FR2849603B1 (fr) * | 2003-01-07 | 2006-09-08 | Centre Nat Rech Scient | Composition pour le transport intracellulaire de macromolecules ou particules biologiques |
| US8034762B2 (en) * | 2004-09-02 | 2011-10-11 | Cognosci, Inc. | Treatment of subarachnoid hemorrhage with Apo E analogs |
| EP1796708A4 (en) * | 2004-09-02 | 2009-07-08 | Cognosci Inc | IMPROVED APO-E ANALOGS AND USE METHOD THEREFOR |
| EP2190868A4 (en) * | 2007-07-31 | 2011-11-23 | Cognosci Inc | METHODS OF INHIBITING CALCINEURIN WITH APOE ANALOGS |
| US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
| US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
| US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
| US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
| US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
| US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
| US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
| US10448989B2 (en) | 2009-04-09 | 2019-10-22 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
| US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
| WO2009134876A1 (en) | 2008-04-29 | 2009-11-05 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
| US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
| US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| WO2010138919A2 (en) | 2009-05-28 | 2010-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
| US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
| EP2627274B1 (en) | 2010-10-13 | 2022-12-14 | AngioDynamics, Inc. | System for electrically ablating tissue of a patient |
| FR2968662B1 (fr) | 2010-12-10 | 2013-11-22 | Roussy Inst Gustave | Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation |
| US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
| US10471254B2 (en) | 2014-05-12 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| WO2016100325A1 (en) | 2014-12-15 | 2016-06-23 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
| US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
| US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
| US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
| US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
| EP4014469A4 (en) * | 2019-08-14 | 2023-09-06 | Nokia Technologies Oy | METHOD AND DEVICE FOR HANDLING NON-INTEGRITY-PROTECTED REJECTION MESSAGES IN NON-PUBLIC NETWORKS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2739621B1 (fr) * | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
| US5843903A (en) * | 1995-11-27 | 1998-12-01 | The Administrators Of The Tulane Educational Fund | Targeted cytotoxic anthracycline analogs |
| CA2286877A1 (en) * | 1997-04-14 | 1998-10-22 | The Regents Of The University Of California | Peptide antiestrogen compositions and methods for treating breast cancer |
| FR2767323B1 (fr) * | 1997-08-12 | 2001-01-05 | Synt Em | Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives |
| ATE419273T1 (de) * | 1998-11-13 | 2009-01-15 | Cyclacel Ltd | Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3 |
-
1998
- 1998-11-30 FR FR9815074A patent/FR2786397B1/fr not_active Expired - Fee Related
-
1999
- 1999-11-26 ES ES99972931T patent/ES2242453T3/es not_active Expired - Lifetime
- 1999-11-26 AT AT99972931T patent/ATE293460T1/de not_active IP Right Cessation
- 1999-11-26 AU AU13910/00A patent/AU777811B2/en not_active Ceased
- 1999-11-26 EP EP99972931A patent/EP1135168B1/fr not_active Expired - Lifetime
- 1999-11-26 IL IL14301099A patent/IL143010A0/xx active IP Right Grant
- 1999-11-26 PT PT99972931T patent/PT1135168E/pt unknown
- 1999-11-26 CA CA002352491A patent/CA2352491A1/fr not_active Abandoned
- 1999-11-26 JP JP2000584925A patent/JP2002531420A/ja active Pending
- 1999-11-26 WO PCT/FR1999/002938 patent/WO2000032236A1/fr active IP Right Grant
- 1999-11-26 US US09/857,000 patent/US7399747B1/en not_active Expired - Fee Related
- 1999-11-26 DE DE69924870T patent/DE69924870T2/de not_active Expired - Lifetime
-
2001
- 2001-05-07 IL IL143010A patent/IL143010A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU777811B2 (en) | 2004-11-04 |
| ATE293460T1 (de) | 2005-05-15 |
| EP1135168B1 (fr) | 2005-04-20 |
| PT1135168E (pt) | 2005-09-30 |
| ES2242453T3 (es) | 2005-11-01 |
| DE69924870D1 (de) | 2005-05-25 |
| JP2002531420A (ja) | 2002-09-24 |
| AU1391000A (en) | 2000-06-19 |
| US7399747B1 (en) | 2008-07-15 |
| DE69924870T2 (de) | 2006-02-23 |
| FR2786397A1 (fr) | 2000-06-02 |
| WO2000032236A1 (fr) | 2000-06-08 |
| FR2786397B1 (fr) | 2003-01-10 |
| EP1135168A1 (fr) | 2001-09-26 |
| CA2352491A1 (fr) | 2000-06-08 |
| IL143010A (en) | 2006-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL143010A0 (en) | Peptidic vectors for transporting substances through the hemato-encephalic barrier | |
| MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
| GR3031488T3 (en) | Laminin chains: diagnostic and therapeutic use | |
| MX9504415A (es) | Eteres antivirales de isoesteres de sustrato de proteasa de aspartato. | |
| DE59510531D1 (de) | Behältnis zur Lagerung und Verabreichung von Injektions-, Infusions- und Diagnostikpräparaten | |
| DK651187A (da) | Leveringsvehikel med amphiphil-associeret aktiv bestanddel og fremgangsmaade til dets fremstilling | |
| EP0671920A4 (en) | AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES. | |
| MXPA03005048A (es) | Anticuerpos humanizados que reconocen el peptido amiloideo beta. | |
| WO2000078344A8 (en) | Prion protein peptides and uses thereof | |
| PT750672E (pt) | Sequencias de adn para metaloproteases matriciais, sua preparacao e utilizacao. | |
| EP1286590A4 (en) | PEPTIDE ANALOGUES AND MIMETICS MAY BE USED IN VIVO TO TREAT DISEASES ASSOCIATED WITH AMYLOID OR PSEUDO-AMYLOID PROTEIN ABNORMAL REPLIAGE OR THEIR PATHOLOGICAL PRECURSOR RICH IN BETA-LEAF | |
| EE03856B1 (et) | Erütropoetiini ja rauapreparaatide kasutamine farmatseutilise liitpreparaadi valmistamiseks, farmatseutiline ühispakend ja meetod rauaseisundi määramiseks kehavedelike proovis | |
| FI953093A0 (fi) | Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä | |
| EP0869801A4 (en) | THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS | |
| HU902004D0 (en) | New trombolitic preparations | |
| ZA975028B (en) | Finger-pressure functioning health-aid instrument for improving blood circulation in the human body. | |
| ES2057572T3 (es) | Agentes de reconocimiento. | |
| IL159479A0 (en) | Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis | |
| HUP9903688A2 (hu) | Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására | |
| EP0870036A4 (en) | MAMMALIAN SYNTHETIC ALPHA-N-ACETYLGLUCOSAMINIDASE AND GENE SEQUENCES ENCODING IT | |
| GR880100589A (en) | Metalloporfyrines for the inversion of the toxic activity for the tumors treatment | |
| ATE238840T1 (de) | Einweg-sicherheitsvorrichtung zur blutübertragung | |
| Vashchuk et al. | Clinico-mycologic analysis of the effectiveness of treatment in patients with rubrophytosis of the feet | |
| RU98102148A (ru) | Способ лечения плацентарной недостаточности | |
| Navicharern et al. | Efficacy of pain conrol using Diflunisal high dose, around the clock compare with Paracetamol for Bassini's herniorrhaphy patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |